Phase I/II study of weekly paclitaxel with or without MLN8237 (alisertib), an investigational aurora A kinase inhibitor, in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (OC), or breast cancer (BrC): Phase I results.
Gerald Steven Falchook
Research Funding - Millennium
Barbara Ann Goff
Honoraria - Lilly
Razelle Kurzrock
Research Funding - Millennium
Heidi J. Gray
No relevant relationships to disclose
Lainie P. Martin
No relevant relationships to disclose
Robert L. Coleman
No relevant relationships to disclose
Hua Liu
Employment or Leadership Position - Millennium
Xiaofei Zhou
Employment or Leadership Position - Millennium
Ely Benaim
Employment or Leadership Position - Millennium
Russell Schilder
Honoraria - Millennium